Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML) - Dinardo, CD; Montesinos, P; Schuh, AC; Papayannidis, C; Vyas, P; Wei, AH; Zeidan, AM; Chen, C; Lord-Bessen, J; Yu, P; Shi, L; Guo, S; et al. (American Society of Clinical Oncology, 2022)